iTeos Therapeutics ITOS

$ 8.84 0.34%

Quarterly report 2024-Q2
added 08-08-2024

iTeos Therapeutics Balance Sheet 2011-2024 | ITOS

Annual Balance Sheet iTeos Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-245 M	-280 M	-843 M	-336 M	-19.9 M	-22 M	-	-	-	-	-	-	-
Long Term Debt	4.81 M	3.84 M	4.57 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	1.25 M	836 K	770 K	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	6.36 M	1.88 M	7.32 M	-	-	-	-	-	-	-
Total Current Liabilities	40 M	42 M	304 M	15 M	-	-	-	-	-	-	-	-	-
Total Liabilities	92.4 M	91.7 M	332 M	21.4 M	15.1 M	12.3 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	4.49 M	2.36 M	390 K	-	-	-	-	-	-	-
Retained Earnings	125 M	237 M	141 M	-73.9 M	-35.9 M	-10.8 M	-	-	-	-	-	-	-
Total Assets	668 M	755 M	885 M	345 M	30.7 M	27.4 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	251 M	285 M	849 M	336 M	20 M	-	-	-	-	-	-	-	-
Book Value	575 M	663 M	553 M	323 M	15.7 M	15.1 M	-	-	-	-	-	-	-
Total Shareholders Equity	575 M	663 M	553 M	323 M	-36.1 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet iTeos Therapeutics

	2024-Q2	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	4.24 M	4.81 M	4.81 M	4.43 M	3.76 M	3.84 M	3.73 M	4.03 M	4.46 M	4.57 M	2.38 M	2.5 M	2.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	88 M	92.4 M	79.4 M	80.2 M	76.1 M	91.7 M	144 M	177 M	224 M	332 M	550 M	29.2 M	20.3 M	21.4 M	21.4 M	21.4 M	21.4 M	15.1 M	15.1 M	15.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	79.3 M	125 M	155 M	187 M	222 M	237 M	217 M	216 M	210 M	141 M	-44.2 M	-114 M	-87.4 M	-73.9 M	-73.9 M	-73.9 M	-73.9 M	-35.9 M	-35.9 M	-35.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	752 M	668 M	678 M	704 M	728 M	755 M	778 M	815 M	850 M	885 M	922 M	319 M	333 M	345 M	345 M	345 M	345 M	30.7 M	30.7 M	30.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	251 M	251 M	204 M	216 M	225 M	285 M	752 M	792 M	824 M	849 M	900 M	303 M	321 M	336 M	336 M	336 M	336 M	19.9 M	19.9 M	20 M	-	22.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	664 M	575 M	598 M	624 M	652 M	663 M	634 M	637 M	626 M	553 M	372 M	289 M	313 M	323 M	323 M	323 M	323 M	15.7 M	15.7 M	15.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	664 M	575 M	598 M	624 M	652 M	663 M	634 M	637 M	626 M	553 M	372 M	289 M	313 M	323 M	323 M	323 M	323 M	-36.1 M	-36.1 M	-36.1 M	-15.8 M	-10.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency